The GLP-1 Boom: What Every Patient Should Know Before Taking the Leap

Barely a week goes by without a patient asking me some version of the same question: “My friend is on Ozempic and has lost so much weight — can I take it too?” or “Is Mounjaro safe? Should I just order it online?”

It’s an understandable question. GLP-1 receptor agonists have become one of the most talked-about advances in modern medicine, and the arrival of the first oral versions in 2026 has only accelerated public interest. But these are prescription medications for specific medical conditions — not a shortcut to be self-administered because a friend, a celebrity, or a social media trend recommends it. Here’s what you actually need to know.

What GLP-1 medications do

GLP-1 (glucagon-like peptide-1) receptor agonists mimic a natural gut hormone that regulates blood sugar, slows stomach emptying, and signals fullness to the brain. This combination is why they were originally developed for type 2 diabetes and were later found to produce significant weight loss — leading to a second wave of approvals specifically for obesity management.

The types available today

Injectable options (the original and still the most effective by average weight loss):

• Semaglutide — marketed as Ozempic (diabetes) and Wegovy (weight management), taken as a once-weekly injection.
• Tirzepatide — marketed as Mounjaro (diabetes) and Zepbound (weight management). A dual GLP-1/GIP receptor agonist — it acts on two gut hormone pathways rather than one, and tends to produce greater average weight loss than semaglutide alone.

Oral options — the newer development:

• Oral semaglutide (Rybelsus) — the original pill form, available since 2019, taken fasting each morning at least 30 minutes before food, drink, or other medications.
• Oral semaglutide 25 mg (Wegovy pill) — a higher-dose oral formulation for weight management, launched in early 2026, with the same fasting requirement as Rybelsus.
• Orforglipron (Foundayo) — approved by the FDA in April 2026, this is the first non-peptide oral GLP-1 medicine. Because of its different chemical structure, it does not require fasting or water restrictions and can be taken at any time of day — a genuine convenience advantage, though trial data so far suggests it is somewhat less potent than the injectable options.

Other agents, including CagriSema, are also still in late-stage trials and not yet approved for clinical use. Availability of the newer oral medicines outside the US, including in the UAE, is still expanding, so always check with your physician or pharmacist about what is currently registered and accessible locally.

What every patient should know before starting

• These are prescription medicines for specific indications — type 2 diabetes, or obesity/overweight with a weight-related medical condition. They are not intended for casual or cosmetic use in people who don’t meet those criteria, and “my friend is on it” is not a medical indication.
• They are not a substitute for lifestyle change. Every approval trial paired the medication with diet and physical activity. The drug helps you eat less and manage blood sugar better — it does not replace the need for a sound nutrition and exercise plan.
• Side effects are common and usually manageable, but not trivial. Nausea, vomiting, diarrhea, constipation, and reflux affect a meaningful proportion of users, especially during dose escalation. Gallstones and, rarely, pancreatitis can occur.
• There are real contraindications. These medications should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and caution is needed in those with a history of pancreatitis or severe gastrointestinal disease.
• Sourcing matters. Obtain these medications only through a licensed pharmacy with a genuine prescription from a physician who has actually assessed you — not through unverified online sellers or “research chemical” suppliers.

Lab tests to monitor while on treatment

Your physician will personalize which of these apply to you and how often — not every test is needed for every patient.

The part most people miss: protecting your muscle

This is the piece of the conversation that gets the least attention, and it matters. Studies show that roughly 25–40% of the weight lost on GLP-1 therapy can be lean muscle mass rather than fat — and because total weight loss on these drugs is often large, the absolute amount of muscle lost can be significant, particularly in older adults. Losing muscle isn’t just a cosmetic issue: it affects strength, mobility, metabolic rate, and how well weight stays off after stopping the medication.

The good news: this is largely preventable.

Resistance training — non-negotiable, not optional

• Frequency: 2–3 sessions per week, covering all major muscle groups.
• Focus: Compound movements — squats, lunges, push-ups, rows, deadlifts — which recruit the most muscle per session.
• Intensity: Enough resistance to feel challenging by the last few repetitions, with correct form prioritized over heavy weight.
• Volume: 2–3 sets of 8–12 repetitions per exercise is a reasonable general target.
• Recovery: Allow roughly 48 hours between sessions targeting the same muscle group.

Evidence suggests structured resistance training during GLP-1 therapy can reduce lean mass loss by roughly a third to a half compared with no exercise at all — without blunting fat loss. In practical terms: the patients who combine adequate protein with regular strength training are the ones who end up leaner, stronger, and better able to maintain their results, rather than simply lighter on the scale.

The bottom line

GLP-1 medications — injectable or the newer oral forms — are genuine medical breakthroughs when used for the right patient, at the right dose, under real medical supervision, with periodic monitoring and a plan to protect muscle along the way. They are not a “candy” to be shared between friends based on someone else’s results.

If you’re considering treatment, or are already on one of these medications and haven’t discussed a monitoring and muscle-preservation plan with your doctor, that conversation is worth having.

This article is provided by Al Diyafa Medical Group for general health information only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition.